Across TCGA pan-cancer cohorts, C1orf216 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C1orf216 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher C1orf216 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C1orf216 expression acts as an unfavorable survival marker.
SKCM are the cancer types where C1orf216 Mutation most reproducibly stratifies survival.